Aim The aim of these recommendations is to set forth an individualized approach to the
management of early postmenopausal women (ie, within the first 10 years after natural …

Objective To assess the risk of venous thromboembolism in women using hormone replacement
therapy by study design, characteristics of the therapy and venous thromboembolism, …

L’hypertension artérielle de la grossesse reste, par ses complications, la première cause de
morbidité et de mortalité maternelle et fœtale. La fréquence (5 à 10 % des grossesses) et la …

The cardiovascular safety of widely used combined hormonal contraceptives is still debated.
Newer generations of oral formulations as well as non-oral contraceptives (transdermal and …

… Sitruk-Ware R, Plu-Bureau G. Epidemiology and treatment of benign breast disease:
effect of progestins on breast disease. In: Sitruk-… Geneviève Plu-Bureau … Geneviève Plu-Bureau …

Background Oral oestrogen-replacement therapy (ERT) activates blood coagulation and
increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal …

Background— Oral estrogen therapy increases the risk of venous thromboembolism (VTE)
in postmenopausal women. Transdermal estrogen may be safer. However, currently …

Although there is no need for routine coagulation monitoring with rivaroxaban – an oral,
direct factor Xa inhibitor – a haemostasis assay might be valuable to measure its …

Postmenopausal hormone replacement therapy is associated with a reduction in the
incidence of coronary heart disease. However, inconclusive results have been reported with …

… ; Drs Straczek, Oger, Plu-Bureau, Conard, Barrellier, Meyer, … , Plu-Bureau, Canonico,
and Scarabin contributed to analysis and interpretation of the data; Drs Straczek, Oger, Plu-Bureau, …